GSK-101468/228

Study Sponsor: GSK

Study Title

A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects.

Medicine or Vaccine (generic name)

ropinirole

Sponsor Identification Number

101468/228

Trial Registry Identification Number(#'s)

NCT00363727

Medical Condition

Parkinson Disease

Phase

Phase 3

Link to GSK Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=101468/228

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00363727

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

June 2014